Agree on the call. The 11 Big pharmas caught my attention. I won't utter the "b" word since it rehashes a back and forth that isn't necessary. However if this statement by NP is in fact true, it makes some sense. IMMU finally got approval, then BIg pharma stepped in. We get approval and have 75-100(per NP on the conference call) potential indications that would only be label expansion trials? Pretty sure a big pharma would step up to that plate.... however I feel NP will demand high dollar so it may never happen which is fine. I think it's "b" or bust though because it was already stated NP isn't interested in licensing a bunch of different indications. Too messy. (Please just thumbs down if you don't like the "b" word...I'm sorry I brought it back up and promise not to do it again until next time....not looking to rediscuss)